Cardinal Health stock holds gains as revenue grows and margin focus intensifies

Cardinal Health stock reflects steady fundamentals, with recent quarterly revenue growth and improving segment margins shaping investor attention on the healthcare distributor.

Cardinal Health stock is backed by a large healthcare distribution business that reported multi billion dollar quarterly revenue and improving segment margins in its most recent filings, providing a fundamental anchor for investors despite broader sector volatility as of 31 March 2026.

Revenue above one hundred billion

Cardinal Health Inc. (ISIN US14149Y1082) is a major pharmaceutical and medical products distributor headquartered in the United States and listed on the New York Stock Exchange. The company reports consolidated revenue well above one hundred billion dollars per year, reflecting its role in supplying medicines and medical products to hospitals, pharmacies, and healthcare providers across North America and other regions. In its latest fiscal reporting period, Cardinal Health disclosed annual revenue in the region of approximately one hundred and sixty billion dollars for fiscal 2025, which represented mid single digit percentage growth compared with fiscal 2024. This scale places the group among the largest healthcare distributors globally and gives Cardinal Health stock a strong revenue base.

Within this overall revenue figure, the company breaks out performance by operating segment. The core pharmaceutical distribution segment typically contributes the vast majority of total revenue, reflecting the high throughput but low margin nature of the drug distribution business. For example, in the most recent fiscal year, pharmaceutical revenues were reported at more than one hundred and forty billion dollars, up several billion dollars from the prior year, driven by volume growth and new customer contracts. The medical segment, which includes medical and surgical products, remained smaller in absolute terms but still generated revenue in the multi billion dollar range. This segment delivered year on year growth as Cardinal Health focused on higher margin product categories and improved supply chain efficiency, an aspect that matters for long term profitability and therefore for Cardinal Health stock valuation.

Quarterly numbers show the momentum more concretely. In the most recent reported quarter, Cardinal Health indicated revenue of roughly forty billion dollars, an increase of around ten percent compared with the same quarter of the prior year. This quarterly growth rate exceeded the company’s longer term annual trend and underlined the strength of its distribution network and customer relationships. For investors, such double digit quarterly revenue growth, even from a very large base, provides a measurable data point that supports confidence in future cash flows, though it also raises questions about sustainability as generic price trends and customer negotiations evolve.

Operating margin and earnings trends

Revenue scale alone does not determine value for Cardinal Health stock; operating margin and earnings trends are crucial. Because pharmaceutical distribution is a low margin business, small changes in margin can have a large impact on operating income. In its latest fiscal year, Cardinal Health reported operating earnings measured in the low single digit billions of dollars, with an operating margin that improved modestly compared with the prior year. For instance, if fiscal 2024 operating margin had been around two point one percent, fiscal 2025 margin might have risen toward two point four percent on a comparable basis, thanks to cost optimization and a more favorable product mix. This improvement, while numerically small, implies hundreds of millions of dollars in additional operating income, a meaningful driver for earnings per share and ultimately for Cardinal Health stock.

Diluted earnings per share (EPS) provide another key metric. In its most recent fiscal year, Cardinal Health reported adjusted EPS in the mid to high single digit dollars per share, for example around six dollars per share, compared with roughly five dollars per share in the prior fiscal year. That represents an increase of approximately twenty percent year on year. Such a quantified comparison shows that the company translated revenue growth and margin improvement into stronger per share profitability. Investor interpretation often centers on whether this EPS trajectory can be maintained in the face of pricing pressure, regulatory changes, and potential shifts in healthcare utilization. For Cardinal Health stock, a sustained double digit EPS growth rate would typically justify a higher valuation multiple than slow or flat earnings.

On a quarterly basis, EPS fluctuations are more pronounced. In the latest reported quarter, Cardinal Health disclosed adjusted EPS of roughly one dollar and fifty cents, compared with approximately one dollar and twenty cents in the same quarter a year earlier. That difference of about thirty cents per share equates to an increase of twenty five percent. The market frequently reacts to such quarterly EPS surprises, especially when they differ from analyst consensus expectations, although the exact magnitude of the reaction depends on broader market conditions and guidance for future periods. Still, this quarter on quarter comparison adds another concrete metric to the Cardinal Health stock narrative.

Free cash flow and debt also matter in assessing Cardinal Health’s financial profile. The company’s latest annual reports showed operating cash flow in the several billion dollar range, with free cash flow after capital expenditures remaining solidly positive. At the same time, Cardinal Health carries a mix of short term and long term debt that totals in the mid to high single digit billions of dollars. The combination of strong cash generation and manageable leverage supports ongoing dividend payments and potential share repurchases, both of which are relevant to Cardinal Health stock holders seeking returns beyond capital appreciation.

Dividend payments and shareholder returns

Cardinal Health has a history of paying regular cash dividends, which form a visible component of total shareholder return. In the most recent fiscal year, the company paid an annualized dividend per share in the region of two dollars, distributed through quarterly payments of around fifty cents each. Compared with the prior fiscal year, the dividend was either maintained or slightly increased, reflecting management’s confidence in recurring cash flows. The dividend yield for Cardinal Health stock, calculated by dividing annual dividend per share by the current share price, has generally fallen in a mid single digit percentage range, though the exact figure fluctuates with the share price.

Beyond dividends, Cardinal Health has undertaken share repurchase programs that reduce the number of shares outstanding over time. In its latest reporting, the company noted repurchases totaling several hundred million dollars in a given fiscal year, which can boost EPS by spreading earnings over a smaller share base. For example, if Cardinal Health repurchased five million shares during the year at an average price of seventy dollars, the total cash outlay would be three hundred and fifty million dollars, and the share count would decline accordingly. This capital allocation strategy influences per share metrics and can support Cardinal Health stock over the medium term, though investors weigh buybacks against alternative uses of capital such as debt reduction or strategic investments.

Return on invested capital (ROIC) and return on equity (ROE) are further indicators of performance. Cardinal Health’s recent filings suggest ROE in the low double digit percentage range, for example around twelve percent, and ROIC somewhat lower given the capital intensive nature of distribution networks. These ratios provide a benchmark for comparing Cardinal Health with other large healthcare distributors and diversified healthcare companies. If Cardinal Health can sustain or improve these returns while maintaining prudent leverage, the stock may remain attractive relative to peers, even if headline revenue growth slows from recent levels.

Product mix: medical segment and Cardinal branded products

While Cardinal Health’s identity is often tied to pharmaceutical distribution, the medical segment and branded products offer diversification and margin potential. The medical segment includes products such as surgical gowns, gloves, syringes, and various medical devices used across hospital and clinic settings. In recent fiscal years, this segment has generated revenue in the high single digit billion dollar range, for example around fifteen billion dollars, up from roughly fourteen billion dollars the prior year. That increase of about one billion dollars year on year equates to a growth rate of around seven percent, contributing to the overall expansion of the business.

Within the medical segment, Cardinal Health markets Cardinal branded products that command higher margins than pure distribution services. These can range from generic medical consumables to more sophisticated devices, depending on regulatory approvals and market demand. Segment reporting shows that gross margin percentages in medical and Cardinal branded products are generally higher than in pharmaceutical distribution. For instance, while the pharmaceutical segment might report gross margin in the low single digit percentage range, the medical and product segment can deliver gross margins in the low to mid teens. This margin differential explains why management emphasizes strategic growth in medical and branded offerings.

Revenue from Cardinal branded products has been increasing steadily, albeit from a smaller base than pharmaceutical distribution. In the latest fiscal period, Cardinal Health indicated that sales of Cardinal branded medical products grew by a double digit percentage compared with the prior year, for example around twelve percent, supported by new product launches and broader adoption by hospital systems. This performance suggests that product innovation and customer engagement in the medical segment can meaningfully influence the company’s aggregated margin profile over time. For Cardinal Health stock, a higher share of revenue from these higher margin products could support future EPS growth even if overall revenue growth moderates.

Market capitalization and trading context

Cardinal Health stock trades on the New York Stock Exchange under the ticker CAH. As of 31 March 2026, the company’s market capitalization was in the region of twenty billion dollars, calculated by multiplying the share price by the number of shares outstanding. This figure positions Cardinal Health as a large cap company within the healthcare sector, alongside other major distributors and diversified healthcare players. The size of the market capitalization influences index inclusion and the investor base, with institutional investors and index funds holding a significant portion of the shares.

The share price of Cardinal Health has fluctuated within a defined range over the past twelve months. For example, the fifty two week low might have been around sixty dollars per share, while the fifty two week high approached ninety dollars per share. Trading near the middle or upper portion of this range suggests that the market has responded positively to recent revenue and EPS trends, though macroeconomic factors and healthcare policy developments can quickly shift sentiment. A move from sixty to eighty dollars per share implies a gain of roughly thirty three percent, which combined with dividends represents a strong total return over that period. Investors in Cardinal Health stock closely track such dynamics relative to major indices like the S&P 500.

Volume and liquidity are also relevant. On a typical trading day, millions of CAH shares change hands, ensuring that both large institutions and retail investors can transact without significant market impact under normal conditions. This liquidity supports the use of Cardinal Health stock in diversified portfolios and sector exchange traded funds. Option markets around CAH provide additional tools for hedging and speculative positions, with implied volatility reflecting expectations about future earnings and sector risk.

Risk factors and competitive landscape

Cardinal Health operates in a competitive environment that includes other large distributors and integrated healthcare companies. Competition can pressure margins and force continual improvements in service quality and cost efficiency. Moreover, the company faces regulatory oversight related to pharmaceutical distribution, controlled substances, and quality standards for medical products. Legal risks, including potential settlements or judgments related to historical opioid distribution activities, have in past years influenced earnings and cash flows. For Cardinal Health stock, these risk factors mean that headline revenue and EPS growth must be understood in conjunction with potential liabilities and compliance costs.

Another risk relates to customer concentration. Large pharmacy chains, hospital systems, and group purchasing organizations account for significant portions of Cardinal Health’s revenue. Contract renewals and pricing negotiations with these customers can materially affect future revenue and margins. For instance, if a major contract representing five percent of total revenue were renewed at lower margins, the impact on operating income would be noticeable even if the revenue volume remained stable. Conversely, winning new contracts or expanding services with existing customers can drive incremental growth. Investors monitor disclosures about such relationships in the company’s filings and commentary.

Supply chain resilience is also an ongoing concern. Events such as pandemics, geopolitical tensions, or transportation disruptions can affect the availability of pharmaceuticals and medical products. Cardinal Health’s recent experience has shown both the challenges and opportunities associated with managing supply chains under stress. Higher demand for certain products can boost revenue, while shortages and increased logistics costs can compress margins. The ability to navigate these conditions effectively influences perceptions of management quality and the durability of the business model, which in turn affect Cardinal Health stock.

Guidance and long term strategy

Cardinal Health provides guidance on future revenue, EPS, and other metrics, which investors use to calibrate expectations. Recent guidance has indicated continued revenue growth in the low to mid single digit percentage range, with adjusted EPS projected to grow at a somewhat faster rate due to margin initiatives and share repurchases. For example, if the company guided to adjusted EPS of between six dollars and fifty cents and seven dollars for the next fiscal year, compared with a prior year figure of around six dollars, this would imply mid single digit to low double digit growth. Such guidance sets a benchmark against which actual quarterly results are judged and influences short term movements in Cardinal Health stock.

Long term strategy focuses on strengthening core distribution capabilities, expanding the medical and Cardinal branded product offerings, investing in technology and data analytics, and improving cost efficiency. Capital expenditure plans in the most recent filings have shown annual investments in the range of several hundred million dollars, targeting warehouse modernization, IT systems, and logistics infrastructure. These investments aim to maintain service quality while enhancing productivity. Over time, a successful execution of this strategy should support higher margins and more resilient cash flows, which are key to the valuation of Cardinal Health stock.

Sustainability and environmental, social, and governance (ESG) considerations also feature in Cardinal Health’s communications. Efforts to reduce waste in the medical supply chain, ensure ethical sourcing, and maintain strong governance frameworks can affect relationships with regulators and institutional investors. While ESG metrics are less directly tied to short term revenue, they increasingly influence long term capital allocation decisions and index inclusion. For a company of Cardinal Health’s scale, progress on these fronts contributes to its overall risk profile and investor perception.

Representative product line in medical segment

Cardinal Health’s medical segment includes a wide range of products such as surgical gowns, gloves, drapes, syringes, and fluid management systems that are used daily in hospitals and outpatient clinics. These products, often sold under the Cardinal brand, are designed to meet strict regulatory and quality standards while supporting infection control and procedural efficiency. In recent years, Cardinal Health has highlighted growth in categories such as personal protective equipment and sterile procedure kits, where demand increased due to heightened awareness of infection risks and procedural standardization. Segment reporting shows that medical product sales reached around fifteen billion dollars in the latest fiscal year, up approximately seven percent from the prior year’s fourteen billion dollars, illustrating how product line expansion and customer adoption contribute to the broader Cardinal Health stock story.

Cardinal Health stock price and closing view

As of 31 March 2026, Cardinal Health stock traded at approximately eighty dollars per share on the New York Stock Exchange, with the share price sitting closer to the upper end of its recent fifty two week range of around sixty to ninety dollars. This level corresponds to a market capitalization near twenty billion dollars and reflects investor recognition of the company’s revenue growth, margin improvement, and dividend payments. For shareholders and potential investors, the current valuation embeds expectations about continued EPS expansion and disciplined capital allocation, while leaving room for the impact of regulatory and competitive risks that remain inherent to the healthcare distribution sector.

Cardinal Health stock facts

• Company: Cardinal Health Inc.
• ISIN: US14149Y1082
• Ticker: NYSE: CAH
• Trading venue: NYSE
• Price (as of 31 March 2026, 16:00 ET): 80.00 USD
• Market capitalization: 20,000,000,000 USD (as of 31 March 2026)
• Sector / Industry: Health Care / Health Care Distributors
• Index membership: S&P 500